Conversation

Notices

1. Ars Technica (arstechnica@mastodon.social)'s status on Wednesday, 04-Oct-2023 23:46:59 JST Ars Technica

   Novavax’s updated protein-based COVID vaccine finally authorized by FDA

   The shot already has CDC signoff and is available to everyone 12 and up.

   https://arstechnica.com/health/2023/10/novavaxs-updated-protein-based-covid-vaccine-finally-authorized-by-fda/?utm_brand=arstechnica&utm_social-type=owned&utm_source=mastodon&utm_medium=social

   • Silversalty (silversalty@mastodon.social)'s status on Thursday, 05-Oct-2023 00:07:07 JST Silversalty

     in reply to

     @arstechnica
     In the past the Novavax vaccine was not as widely available as the mRNA versions. Will this be the case again? Also, with costs no longer being covered, how much will these vaccines cost?

     So much about this controlled market seems, not for safety and public benefit, but instead, for its exploitation.